Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

ELI LILLY AND COMPANY

(LLY)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
10/14/2019 10/15/2019 10/16/2019 10/17/2019 10/18/2019 Date
107.9(c) 109.7(c) 107.95(c) 108.46(c) 108.64(c) Last
1 371 611 1 761 041 2 316 857 2 268 095 2 192 142 Volume
-0.42% +1.67% -1.60% +0.47% +0.17% Change
More quotes
Financials (USD)
Sales 2019 22 226 M
EBIT 2019 6 071 M
Net income 2019 8 146 M
Debt 2019 11 234 M
Yield 2019 2,32%
Sales 2020 23 676 M
EBIT 2020 7 181 M
Net income 2020 5 615 M
Debt 2020 7 779 M
Yield 2020 2,52%
P/E ratio 2019 12,4x
P/E ratio 2020 17,0x
EV / Sales2019 4,98x
EV / Sales2020 4,53x
Capitalization 99 453 M
More Financials
Company
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (47.6%): products for treating osteoporosis, diabetes, and growth problems; - oncology (17.4%); - veterinary medicine (12.8%); - cardiovascular... 
Sector
Pharmaceuticals
Calendar
10/23 | 06:25amEarnings Release
More about the company
Surperformance© ratings of Eli Lilly and Company
Trading Rating : Investor Rating :
More Ratings
Latest news on ELI LILLY AND COMPANY
10/16ELI LILLY AND : Terns pharmaceuticals to present positive preclinical data on fx..
AQ
10/16ELI LILLY AND : Phase 3 Pegilodecakin Study Misses Main Endpoint in Pancreatic C..
DJ
10/16ELI LILLY AND : Lilly Announces Phase 3 Study in Patients with Metastatic Pancre..
PU
10/15ELI LILLY AND : Correction to Eli Lilly Promoting Women Article on Oct. 15 -- Jo..
DJ
10/15ELI LILLY AND : Inside Eli Lilly's Successful Strategy to Promote More Women -- ..
DJ
10/14ELI LILLY AND COMPANY : - Lilly's REYVOW, The First and Only Medicine in a New C..
AQ
10/14ELI LILLY AND : PhRMA - Remembering Harrison Cook, Vice President for Internatio..
AQ
10/14ELI LILLY AND COMPANY : - Lilly Presents Positive Results for Taltz in Pediatric..
AQ
10/12ELI LILLY AND : Lilly Presents Positive Results for Taltz® (ixekizumab) in Pedia..
PU
10/11ELI LILLY AND : Lilly's REYVOW™ (lasmiditan), The First and Only Medicine ..
PU
10/11ELI LILLY AND : FDA Approves Eli Lilly's Reyvow for Migraine Patients
DJ
10/09ELI LILLY AND COMPANY : - Lilly to Unveil New Data for the Treatments of Complex..
AQ
10/08ELI LILLY AND : Lilly to Unveil New Data for the Treatments of Complex Dermatolo..
PU
10/07PFENEX : Gets FDA Approval for Forteo Equivalent Candidate PF708
DJ
10/04ELI LILLY AND COMPANY : - New Head-to-Head Data Show Taltz Superiority versus TR..
AQ
More news
News in other languages on ELI LILLY AND COMPANY
10/16ELI LILLY : échec d'un essai dans le cancer pancréatique
10/10ELI LILLY AND COMPANY : Files Form 3 and 4
10/03ELI LILLY AND COMPANY : Lilly Announces Voluntary Delisting from Euronext Paris
09/30Les valeurs à suivre aujourd'hui à Wall Street - Lundi 30 septembre 2019
09/30EN DIRECT DES MARCHES : EDF, Safran, Bonduelle, Adocia, Antalis, Norwegian Ai..
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Sector news : Pharmaceuticals - NEC
03:52pJOHNSON & JOHNSON : J&J Recalls Baby Powder on Asbestos Concern -- 3rd Update
DJ
02:48aJ&J Recalls Baby Powder For Asbestos -- WSJ
DJ
10/18More Money Demanded in Opioid Settlement Talks -- Update
DJ
10/18More Money Demanded in Opioid Settlement Talks
DJ
10/18JOHNSON & JOHNSON : J&J Recalls Baby Powder on Asbestos Concern -- 2nd Update
DJ
More sector news : Pharmaceuticals - NEC
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 127,33  $
Last Close Price 108,64  $
Spread / Highest target 33,5%
Spread / Average Target 17,2%
Spread / Lowest Target -14,4%
EPS Revisions
Managers
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Myles Oneill Senior VP & President-Manufacturing Operations
Joshua L. Smiley Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Aarti S. Shah Chief Information Officer & SVP-IT
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY-6.12%99 453
JOHNSON & JOHNSON5.52%337 021
ROCHE HOLDING AG18.49%250 869
MERCK AND COMPANY10.82%216 813
PFIZER-16.47%201 662
NOVARTIS15.95%198 751